TransCode Therapeutics Inc. has announced the publication of preclinical research supporting the therapeutic potential of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, demonstrates that TTX-MC138, delivered intravenously, effectively targets glioblastoma tumors in murine models and suppresses the miR-10b target, resulting in extended survival in aggressive glioblastoma models. The findings support the clinical development of TTX-MC138 for GBM patients. Preclinical studies, including pharmacokinetics, biodistribution, and toxicity assessments, have been completed, and the formulation has shown safety in Phase I clinical trials in patients with non-CNS cancers. A Phase 1a clinical trial is currently evaluating TTX-MC138 in metastatic disease, with a Phase 2a trial anticipated to begin in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE56569) on January 06, 2026, and is solely responsible for the information contained therein.